Advertisement

Advertisement

Prostate Cancer

Lu-177 Vipivotide Tetraxetan Shows Benefit in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

On December 5, Novartis announced the pivotal phase III PSMAfore study of lutetium (Lu-177) vipivotide tetraxetan, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint. The therapy demonstrated a statistically significant and clinically meaningful...

Prostate Cancer
Genomics/Genetics

Ethnic Diversity and Disparities in Access to Genetic Testing May Impact Prostate Cancer Development and Treatment, Research Shows

More than 1.4 million patients were diagnosed with prostate cancer in 2020 globally, but the molecular characteristics of the disease remain unexplored for the majority of patients around the world. In the final days of the Movember campaign, which every year in November aims to raise awareness of...

Prostate Cancer

Addition of Enzalutamide to Salvage Radiotherapy in Patients With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

In a phase II trial (SALV-ENZA) reported in the Journal of Clinical Oncology, Phuoc T. Tran, MD, PhD, and colleagues found that the addition of enzalutamide to salvage radiotherapy improved freedom from prostate-specific antigen (PSA) progression in patients with biochemically recurrent prostate...

Breast Cancer
Prostate Cancer

Intraindividual Comparison of F-18–NaF PET-CT vs Tc-99m–MDP SPECT in Detecting Bone Metastasis in High-Risk Prostate and Breast Cancers

In a Canadian phase III trial (MITNEC-A1) reported in The Lancet Oncology, Bénard et al found that fluorine-18–sodium fluoride (F-18–NaF) positron-emission tomography-computed tomography (PET-CT) was more accurate in detecting skeletal metastases vs technetium-99m–methylene diphosphonate...

Prostate Cancer

ASCO Treatment Guidance for Metastatic Castration-Resistant Prostate Cancer Updated to Include LuPSMA

An updated ASCO guideline recommends lutetium-177–labeled PSMA-617 (LuPSMA), a targeted radioligand therapy, for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with one prior line of androgen receptor pathway...

Prostate Cancer

Lutetium Lu-177 Vipivotide Tetraxetan for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

On March 23, 2022, the radioligand therapeutic agent lutetium Lu-177 vipivotide tetraxetan was approved for treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with an androgen receptor pathway inhibitor ...

Prostate Cancer

Sequencing of Short-Duration ADT With Radiotherapy in Nonmetastatic Prostate Cancer

In a pooled analysis (SANDSTORM) reported in the Journal of Clinical Oncology, Ma et al found that concurrent/adjuvant short-term androgen-deprivation therapy (ADT) with prostate-only radiotherapy (PORT) was associated with better outcomes in multiple measures vs neoadjuvant/concurrent ADT with...

Prostate Cancer

Biomarker Assessment for Benefit of LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

In a prespecified analysis from the Australian phase II TheraP trial reported in The Lancet Oncology, Buteau et al found that higher gallium-68–labeled PSMA-11 positron-emission tomography (PSMA-PET) mean standardized uptake values (SUVmean) were associated with a greater likelihood of...

Prostate Cancer

RADICALS-HD Trial: Duration of Androgen-Deprivation Therapy With Radiotherapy After Radical Prostatectomy

The addition of 24 months of androgen-deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved the time to salvage therapy in patients with prostate cancer, according to the preliminary results from the RADICALS-HD trial...

Prostate Cancer

PSA Screening Rates and Incidence of Metastatic Prostate Cancer at VHA Facilities

In a retrospective cohort study reported in JAMA Oncology, Bryant et al found that prostate-specific antigen (PSA) screening rates at Veterans Health Administration (VHA) facilities declined between 2005 and 2019—and that diagnoses of metastatic prostate cancer increased over the same time period....

Prostate Cancer

Addition of Cediranib to Olaparib for Metastatic Castration-Resistant Prostate Cancer

As reported in the Journal of Clinical Oncology by Kim et al, the phase II National Cancer Institute 9984 trial has shown prolonged radiographic progression-free survival with the addition of cediranib to olaparib in patients with metastatic castration-resistant prostate cancer. Study Details In...

Prostate Cancer

Continuous Enzalutamide Plus Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer With Disease Progression on Enzalutamide

In the European phase IIIb PRESIDE trial reported in The Lancet Oncology, Merseburger et al found that treatment with docetaxel and continuing enzalutamide vs placebo improved progression-free survival in patients with metastatic castration-resistant prostate cancer who had disease progression on...

Prostate Cancer

Multimodal Artificial Intelligence Models May Offer an Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer

NRG Oncology investigators analyzed clinical and digital histopathology data from five phase III prostate cancer trials (NRG/RTOG 9202, 9408, 9413, 9910, and 0126) to develop and validate multimodal artificial intelligence models (MMAI) that could outperform the National Comprehensive Cancer...

Prostate Cancer

EXTEND Trial: Metastasis-Directed Radiation Therapy Plus Hormone Therapy May Improve Progression-Free Survival in Patients With Advanced Prostate Cancer

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were...

Issues in Oncology
Gynecologic Cancers
Prostate Cancer

Sexual Side Effects of Cancer Treatment Often Unaddressed With Female Patients

A new study has found that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs. Among patients receiving brachytherapy for prostate or cervical cancer at a high-volume cancer...

Prostate Cancer

A Urologic Surgeon Shares His Insights on Robotic Radical Prostatectomy

In 2000, the da Vinci Surgical System broke new ground by becoming the first robotic surgery system approved by the U.S. Food and Drug Administration for general laparoscopic surgery. In its early years, robot-assisted radical prostatectomy was characterized by some in the surgical community as an...

Prostate Cancer

Providing a Tailored Approach to Prostate Cancer Care for Gay and Bisexual Men

It is estimated that one in eight men will be diagnosed with prostate cancer in his lifetime. The disease is so prevalent, and other than skin cancer, it is the most common cancer diagnosed in American men. According to the American Cancer Society, this year, about 268,490 new cases of prostate...

Prostate Cancer

PCS5 Trial: Long-Term Outcomes of Moderately Shortened Radiation Course for High-Risk Prostate Cancer

A randomized study has confirmed that patients with high-risk prostate cancer can be treated with 5 vs 8 weeks of radiation therapy. The phase III clinical trial is the first to confirm the safety and efficacy of a moderately shortened course of radiation exclusively for patients with high-risk...

Prostate Cancer

RADICALS-HD Trial: Duration of Androgen-Deprivation Therapy With Radiotherapy After Radical Prostatectomy

The addition of 24 months of androgen-deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved the time to salvage therapy in patients with prostate cancer, according to the preliminary results from the RADICALS-HD trial...

Prostate Cancer

Darolutamide Combined With Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

On August 5, 2022, darolutamide was approved for use in combination with docetaxel for patients with metastatic hormone-sensitive prostate cancer.1 Approval was based on the double-blind ARASENS trial (ClinicalTrials.gov identifier NCT02799602), in which 1,305 patients were randomly assigned to...

Prostate Cancer
Survivorship

Health-Related Quality of Life for Survivors of Metastatic Prostate Cancer

Survivors of prostate cancer originally diagnosed with metastatic disease may experience significantly worse health-related quality of life than those diagnosed with early-stage disease and individuals without a cancer history across all domains, according to a new study by Zheng et al published in ...

Prostate Cancer

2-Year Toxicity With Conventional IMRT vs Hypofractionated SBRT for Localized Prostate Cancer

As reported in The Lancet Oncology by Tree et al, an analysis from the phase III PACE-B trial has shown no difference in 2-year genitourinary or gastrointestinal toxicity with conventionally fractionated/moderately hypofractionated intensity-modulated radiotherapy (IMRT) vs highly hypofractionated...

Prostate Cancer
Genomics/Genetics

Genomic Testing May Aid in Identifying Patients of African Descent With High-Risk Prostate Cancer

Black patients of African descent tend to be diagnosed more frequently with prostate cancer and have higher mortality rates than patients of other races and ethnicities. Despite this substantial disparity, few prospective studies focused on maximizing the recruitment of African American patients...

Prostate Cancer
Genomics/Genetics

Prostate Tumor Biology May Be Influenced by Genetic Ancestry

Certain genetic variants found in prostate tumors of men of African descent were associated with African ancestry, according to two studies presented at the 15th American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial and Ethnic Minorities...

Cost of Care
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer

Costs of Cancer Treatment for Younger, Privately Insured Patients

A new, large study led by researchers at the American Cancer Society (ACS) and The University of Texas MD Anderson Cancer Center showed the rising costs of cancer treatment led to increases in total costs of care, and when compounded with greater cost-sharing, increased out-of-pocket costs for...

Prostate Cancer

Rezvilutamide vs Bicalutamide Combined With ADT in High-Volume Metastatic Hormone-Sensitive Prostate Cancer

As reported in The Lancet Oncology by Gu et al, interim analyses of the phase III CHART trial have shown improved radiographic progression-free survival and overall survival with the novel androgen receptor inhibitor rezvilutamide vs bicalutamide when both were combined with androgen-deprivation...

Prostate Cancer

Patient-Reported Outcomes With the Addition of Olaparib to Abiraterone in Castration-Resistant Prostate Cancer

As reported in The Lancet Oncology by Fred Saad, MD, FRCS, and colleagues, an analysis of a phase II trial found no significant differences in health-related quality of life or pain measures with the addition of olaparib to abiraterone in patients with metastatic castration-resistant prostate...

prostate cancer

Neal D. Shore, MD, on Prostate Cancer: Biomarker Analysis, Enzalutamide, and Active Surveillance

Neal D. Shore, MD, of Carolina Urologic Research Center/Genesis Care, discusses new data from the ENACT trial, which showed that patients with prostate cancer and the RNA biomarkers PAM50 and AR-A were likely to have better outcomes with enzalutamide treatment. The results suggest that such RNA biomarkers may help to identify patients who may benefit from enzalutamide treatment compared with active surveillance (Abstract 1385P).

Prostate Cancer

PRESTO: Treatment Beyond Androgen-Deprivation Therapy for Relapsed Patients With High-Risk Prostate Cancer

Aggarwal et al presented data from PRESTO (AFT-19) at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA63), the first trial to evaluate whether intensifying treatment beyond androgen-deprivation therapy (ADT) by adding apalutamide with or without abiraterone acetate plus...

Prostate Cancer

Long-Term Findings of Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer

As reported in the Journal of Clinical Oncology by Deek et al, long-term follow-up of the pooled phase II STOMP and ORIOLE trials suggest maintained benefit of metastasis-directed therapy vs observation in patients with oligometastatic castration-sensitive prostate cancer. Study Details As noted by ...

Prostate Cancer
Genomics/Genetics

Two New Studies Find Aggressive Prostate Cancer May Be Linked to Ancestral Heritage

Two studies published simultaneously by Jaratlerdsiri et al in Nature and Gong et al in Genome Medicine have identified genetic signatures explaining ethnic differences in the severity of prostate cancer, particularly in sub-Saharan Africa. Through genetic sequencing of prostate cancer tumors from...

Prostate Cancer

Success Story in Prostate Cancer for Many Men

“I now think of prostate cancer as a story of success for many men, given the advancements in both research and treatment options over the past decade,” Behfar Ehdaie, MD, MPH, told The ASCO Post. Dr. Ehdaie is lead author of a study that found MRI-guided focused ultrasound focal therapy is safe...

Prostate Cancer

MRI-Guided Ultrasound Focal Therapy May Delay or Avoid Prostatectomy or Radiotherapy in Patients With Intermediate-Risk Prostate Cancer

MRI-guided focused ultrasound focal therapy produced “a high degree of success” and “a low rate of genitourinary adverse events” when used to treat select patients with intermediate-grade prostate cancer, Behfar Ehdaie, MD, MPH, and colleagues reported in The Lancet Oncology.1 Dr. Ehdaie is...

Prostate Cancer

Surviving Advanced Prostate Cancer Has Made Me a More Empathetic Physician

My diagnosis of terminal prostate cancer 3 years ago was filled with irony. As an interventional radiologist, I have treated hundreds of patients with advanced prostate cancer, and I knew my prognosis wasn’t good. After experiencing some of the common symptoms of the cancer, including voiding...

Prostate Cancer

Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up

Radiotherapy to the prostate in addition to standard treatment may improve survival for some men with advanced prostate cancer without detriment to quality of life, long-term study results from the STAMPEDE trial confirmed. These findings were published by Chris C. Parker, MD, and colleagues in...

Prostate Cancer

GnRH Agonist Therapy for Prostate Cancer and Cardiovascular Disease Risk in Men With Type 2 Diabetes

In a Swedish population-based cohort study reported in JAMA Network Open, Lin et al found that men with type 2 diabetes receiving gonadotropin-releasing hormone (GnRH) agonists for prostate cancer were more likely to have an increased risk for developing cardiovascular disease compared with those...

Prostate Cancer

PSA Screening and Prostate Cancer Mortality Among Black and White Veterans

In a study reported in JAMA Oncology, Sherer et al found that prostate-specific antigen (PSA) screening was associated with reduced prostate cancer mortality among both non-Hispanic Black and non-Hispanic White U.S. veterans who developed prostate cancer. Annual vs some screening was associated...

Prostate Cancer

FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer

On August 5, 2022, the U.S. Food and Drug Administration approved darolutamide (Nubeqa) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer. The evaluation of efficacy was based on ARASENS (ClinicalTrials.gov identifier NCT02799602), a...

Prostate Cancer

Second Primary Cancer Risk After Primary Radiotherapy vs Surgery or Other Treatment in Veterans With Localized Prostate Cancer

In a retrospective cohort study reported in JAMA Network Open, Bagshaw et al found that the risk of a second primary cancer at more than 1 year from diagnosis was significantly greater among U.S. veterans with localized prostate cancer who received primary radiotherapy vs those who received surgery ...

Prostate Cancer

Media Emphasis on Urinary Symptoms May Delay Diagnosis of Early Prostate Cancer

According to Cancer Research UK, over 52,000 men are diagnosed with prostate cancer each year in the UK, and there are more than 12,000 deaths. Over three-quarters (78%) of men diagnosed with the disease survive for over 10 years, but this proportion has barely changed over the past decade in the...

Prostate Cancer

Expert Point of View: Susan Slovin, MD, PhD

Invited discussant Susan Slovin, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, pointed out there are no relevant serum biomarkers for disease progression and the challenges of interpreting response in metastatic castration-resistant prostate cancer. “We should have more definitive...

Prostate Cancer

LuPSMA Improves Progression-Free Survival vs Cabazitaxel in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) achieved longer progression-free survival with fewer toxicities compared with cabazitaxel in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer whose disease...

Prostate Cancer

EAU22: Trial Shows New Imaging Technology May Be Less Accurate Than MRI in Detecting Prostate Cancer

A team of researchers in Australia and New Zealand reported that magnetic resonance imaging (MRI) scans may be able to detect prostate cancer more accurately than the newer, prostate-specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) scanning technique. The...

Prostate Cancer

Addition of Enzalutamide to Active Surveillance in Low- or Intermediate-Risk Localized Prostate Cancer

As reported in JAMA Oncology by Neal D. Shore, MD, FACS, and colleagues, the phase II ENACT trial has shown a reduced risk of disease progression with the addition of enzalutamide to active surveillance in patients with low- or intermediate-risk localized prostate cancer. Study Details In the...

Prostate Cancer

EAU22: New Research Supports Risk-Based Prostate Cancer Screening

Data from the world’s largest prostate cancer screening study provides further evidence to support the introduction of a targeted screening program for the disease, said researchers. In 2009, the European Randomised Study of Screening for Prostate Cancer (ERSPC) showed that screening can reduce...

Prostate Cancer

EAU22: Study Finds Gut Microbes Differ in Patients With Prostate Cancer vs Those With Benign Biopsy Results

Researchers have found a significant difference in the gut microbiota of patients with prostate cancer compared with those who have benign biopsies. Although the finding is an association, it could partly explain the relationship between lifestyle effects and geographic differences in prostate...

Prostate Cancer

Is Focal Therapy With MRI-Guided Focused Ultrasound Safe and Effective for Grade Group 2 or 3 Prostate Cancer?

In a phase IIb study reported in The Lancet Oncology, Ehdaie et al found that focal ablation with magnetic resonance imaging (MRI)-guided focused ultrasound successfully treated a high proportion of patients with grade group 2 or 3 prostate cancer. As stated by the investigators, “Men with grade...

Prostate Cancer

Cabozantinib and Atezolizumab for Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Post–Hormonal Therapy

As reported in The Lancet Oncology by Neeraj Agarwal, MD, and colleagues, findings in the expansion cohort of the phase Ib COSMIC-021 trial indicate activity of the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer whose disease progressed ...

Prostate Cancer

William Catalona, MD, on the Evolution of Views Regarding Active Surveillance in Men With Low-Risk Prostate Cancer

William Catalona, MD, Professor of Urology at Northwestern University’s Feinberg School of Medicine, and past Principal Investigator on the Northwestern-based prostate SPORE, explained the evolution of his views regarding active surveillance in men with low-risk prostate cancer. Although...

Prostate Cancer

Rates of Active Surveillance Rising Among Men With Low-Risk Prostate Cancer but Still Suboptimal

Most men with low-risk prostate tumors now opt for active surveillance, but overtreatment remains a problem, according to data presented during the 2022 American Urological Association (AUA) Annual Meeting.1 A retrospective analysis of more than 20,000 patients with low-risk prostate cancer showed...

Advertisement

Advertisement

Advertisement